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Abstract
Antiretroviral (ARV) drug use was analyzed in HIV-uninfected women in an observational
cohort study conducted in 10 urban and periurban communities in the United States with
high rates of poverty and HIV infection. Plasma samples collected in 2009–2010 were
tested for the presence of 16 ARV drugs. ARV drugs were detected in samples from 39
(2%) of 1,806 participants: 27/181 (15%) in Baltimore, MD and 12/179 (7%) in Bronx, NY.
The ARV drugs detected included different combinations of non-nucleoside reverse tran-
scriptase inhibitors and protease inhibitors (1–4 drugs/sample). These data were analyzed
in the context of self-reported data on ARV drug use. None of the 39 women who had ARV
drugs detected reported ARV drug use at any study visit. Further research is needed to
evaluate ARV drug use by HIV-uninfected individuals.
Introduction
The prevalence of antiretroviral (ARV) drug use among HIV-uninfected individuals is unclear.
In the United States (US), ARV drugs are used by HIV-uninfected individuals for pre- and post-
exposure prophylaxis (PrEP and PEP) [1–3]. ARV drugs, such as nucleoside/nucleotide reverse
transcriptase inhibitors (NRTIs), are also used to treat chronic hepatitis B virus infection [4].
Several reports also indicate that some ARV drugs are used for recreational purposes [5,6]. ARV
drug resistance can emerge if individuals become HIV infected while using ARV drugs.
PLOSONE | DOI:10.1371/journal.pone.0140074 October 7, 2015 1 / 9
OPEN ACCESS
Citation: Chen I, Clarke W, Ou S-S, Marzinke MA,
Breaud A, Emel LM, et al. (2015) Antiretroviral Drug
Use in a Cohort of HIV-Uninfected Women in the
United States: HIV Prevention Trials Network 064.
PLoS ONE 10(10): e0140074. doi:10.1371/journal.
pone.0140074
Editor: Nicolas Sluis-Cremer, University of
Pittsburgh, UNITED STATES
Received: July 13, 2015
Accepted: September 21, 2015
Published: October 7, 2015
Copyright: © 2015 Chen et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper.
Funding: This work was supported by the HIV
Prevention Trials Network (HPTN, UM1-AI068613).
The HPTN is funded by the National Institute of
Allergy and Infectious Diseases; National Institute of
Drug Abuse; National Institute of Mental Health;
Office of AIDS Research, National Institutes of
Health; and Department of Health and Human
Services.
HIV Prevention Trials Network (HPTN) 064 was an observational study conducted in
2009–2010 that assessed behaviors and HIV incidence among women in the US at increased
risk for HIV infection who resided in areas of poverty and high HIV prevalence [7,8]. Women
in HPTN 064 reported high prevalence of risky sexual behaviors and drug and alcohol use [7].
HIV incidence was estimated using a multifaceted approach that included analysis of HIV
seroconversion [8]. The annual HIV incidence in the cohort was 0.32% (95% confidence inter-
val [CI]: 0.14%-0.74%). One woman who acquired HIV infection during the study had unde-
tectable HIV RNA at her first HIV positive visit and had emtricitabine (FTC) and tenofovir
(TFV) detected in her plasma (unpublished data). These drugs are components of Truvada1
(co-formulated FTC/TFV), which was later approved by the US Food and Drug Administra-
tion (FDA) for use as PrEP [1]. Some HIV-uninfected women in HPTN 064 also reported
prior ARV drug use for PEP. In this report, we used a low cost, high-throughput ARV drug
assay to estimate the prevalence and patterns of ARV drugs detected in plasma samples from
HIV-uninfected women enrolled in HPTN 064.
Methods
Study cohort
HPTN 064 enrolled 2,099 women who reported no prior HIV diagnosis at ten urban and peri-
urban communities in the US: Atlanta and Decatur, GA; Baltimore, MD; Durham and Raleigh,
NC; Bronx and Harlem, NY; north and south Newark, NJ; and Washington, DC [7–9].
Women were recruited at community venues using time-space sampling and were followed for
up to one year [10]. Study participants reported unprotected sex with a man and at least one
other risk factor (individual or partner) for HIV infection in the six months prior to study
enrollment. Participants completed audio computer-assisted self-interviews at each study visit
(enrollment, 6 months, and 12 months). Women were asked about prior ARV drug use at the
time of study enrollment (“Has the participant ever taken any antiretroviral medications?”)
and at each follow-up visit (“Since her last visit, has the participant started taking any antiretro-
viral medications or changed antiretroviral medications?”). Participants who answered “Yes”
were asked to specify the reasons for their ARV drug use (“Why did the participant take antire-
troviral medications?”), which included taking ARV drugs for PrEP, PEP, treatment of HIV
disease (i.e., ARV treatment [ART]; follow-up visits only), or “other” reasons. Women also
received HIV testing and provided plasma samples for laboratory analyses at each study visit.
This analysis included the 1,806 HIV-uninfected women who had a sample available from
their last study visit. Randomly-selected enrollment samples from 369 of the 1,806 women
(approximately 40 from each study site) were also tested to analyze ARV drug use at the time
of study enrollment.
Laboratory methods
Plasma samples were analyzed retrospectively for the presence of 16 ARV drugs: five NRTIs
(FTC, TFV, lamivudine [3TC], stavudine, and zidovudine [ZDV]), two non-nucleoside reverse
transcriptase inhibitors (NNRTIs; efavirenz [EFV] and nevirapine), and nine protease inhibi-
tors (PIs; atazanavir, amprenavir, darunavir, lopinavir, indinavir [IDV], nelfinavir [NFV],
saquinavir [SQV], tipranavir [TPV], and ritonavir [RTV]). Samples were prepared by combin-
ing 100 μL plasma with 300 μL acetonitrile containing 125 ng/mL deuterated morphine-d3.
The resulting supernatant was then dried and reconstituted with 150 μL water. ARV drugs
were detected using high-performance liquid chromatography (HPLC) coupled with high-res-
olution accurate mass (HRAM) mass spectrometry (MS; Exactive-Orbitrap; Thermo Scientific,
Pittsburgh, PA). The mobile phase system consisted of 10 mM ammonium acetate and 0.1%
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ammonium hydroxide in methanol. Samples were introduced onto a 1.9-μmHypersil Gold
perfluorinated phenyl column at 100% aqueous composition; elution occurred during a 3.25
minute step-and-hold isocratic step to 100% methanol. Positive full-ion MS and all-ion frag-
mentation were conducted at 100,000 and 25,000 resolution, respectively; negative full-ion MS
was conducted at 100,000 resolution. ZDV and EFV were detected using parent-ion scanning
in negative ion mode and fragment identification in positive ion mode. All other ARV drugs
were analyzed in positive ion mode for both the parent and fragment ions. The limit of identifi-
cation for all ARV drugs in this assay was 10 ng/mL.
Statistical methods
Associations between ARV drug detection and individual and partner characteristics were
examined using Fisher’s exact and chi-square tests for categorical variables and Wilcoxon rank
sum tests for continuous variables (SAS, version 9.2; SAS Institute, Cary, NC).
Ethical considerations
All study participants provided written informed consent for participation in the HPTN 064
study. A Certificate of Confidentiality was obtained for HPTN 064, and the study was approved
by institutional review boards at each study site and participating institution: Bronx-Lebanon
Hospital Center; Columbia University Medical Center; Emory University; George Washington
University; Johns Hopkins Medicine; New Jersey Medical School; and University of North
Carolina at Chapel Hill.
Results
Study cohort
The HPTN 064 study is described in detail in a previous report [7]. In this study, 2,065 women
were HIV uninfected at study enrollment [7,8]. Four women acquired HIV infection during
study follow-up and were not included in this report; the remaining 2,061 women were HIV
uninfected at the last study visit. Samples from 255 (12%) of the 2,061 women at the last study
visit were not available for ARV drug testing (the study participants did not consent to addi-
tional testing or did not have plasma available). We analyzed the remaining 1,806 samples
using a multi-drug assay, including 109 (6%) from the enrollment visit, 384 (21%) from the
6-month visit, and 1,313 (73%) from the 12-month visit. For comparison, 369 additional
enrollment samples were tested from a random subset of participants.
ARV drug detection
ARV drugs were detected in 39 (2%) of the 1,806 samples, including samples from 27 (15%) of
the 181 women from Baltimore, MD and 12 (7%) of the 179 women from Bronx, NY (Table 1).
ARV drugs were not detected in samples from women at the other eight communities. None of
the 39 women who had ARV drugs detected reported ARV drug use at any study visit. Among
the 1,767 women who did not have ARV drugs detected, nine (5%) reported ARV drug use at
one of their study visits. These women were enrolled at five study sites (Decatur, GA; Raleigh,
NC; Bronx and Harlem, NY; and Washington, DC). All nine women reported using ARV
drugs for PEP; one woman also reported “intent to sell” when asked about other reasons for
ARV drug use.
In Baltimore, 22 (81%) of the 27 women who had ARV drugs detected had a single drug
detected (EFV or a PI alone); the PIs that were detected alone most frequently were NFV and
SQV. The five remaining women (19%) had multiple ARV drugs detected (multiple PIs or
ARV Drug Use in HIV-UninfectedWomen
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EFV with one or more PIs). In Bronx, nine (75%) of the 12 women who had ARV drugs
detected had a single drug detected (EFV or IDV). The remaining three women (25%) had
EFV with IDV detected.
Univariate analyses were performed to evaluate the association of demographic and behav-
ioral factors with ARV drug detection (Tables 2–4). In Baltimore, ARV drug detection was
associated with race (P = 0.040), childhood abuse (odds ratio [OR]: -6.3; P = 0.049), and having
a partner who was incarcerated within the past five years (OR: 4.7; 95% CI: 1.3–25.3;
P = 0.008). In Bronx, ARV drug detection was associated with older age (mean age difference:
5.3 years; 95% CI: 1.0–9.6 years; P = 0.012). When results from both study sites were combined,
ARV drug detection was significantly associated with childhood abuse (OR: 2.3; 95% CI: 1.1–
5.0; P = 0.015).
We also analyzed enrollment samples from a random subset of the HIV-uninfected women
to assess ARV drug use prior to enrollment (369 women). This randomly-selected subset of
women included 10 of the 41 women from Baltimore who had ARV drugs detected at the last
study visit, and five of the 44 women from Bronx who had ARV drugs detected at the last study
visit. ARV drugs were not detected at enrollment in any of 369 women. Only one of the 369
women reported any prior use of ARV drugs at her enrollment visit, indicating that she had
used ARV drugs for PEP. Among the remaining 1,437 women in the cohort (those who did not
have enrollment samples tested for ARV drugs), only three reported prior ARV drug use at the
enrollment visit; in all three cases, the women indicated that they had used ARV drugs for PEP.
Discussion
We found regionally-distinct patterns of ARV drug use among HIV-uninfected women in this
observational cohort. Overall, 39 (2%) of the women had ARV drugs detected; all 39 women
were from Baltimore or Bronx. Only EFV and PIs were detected. EFV was detected in both Bal-
timore and Bronx. In contrast, several PIs were detected in Baltimore, while only IDV was
detected in Bronx.
Few studies have evaluated ARV drug use in HIV-uninfected women. At the time HPTN
064 was conducted (2009–2010), ARV drugs were not approved by the US FDA for PrEP;
Table 1. Antiretroviral Drugs Detected in Plasma Samples Collected at the Last Study Visit.
Overall (n = 1,806) Baltimore (n = 181) Bronx (n = 179)
ARV drug(s) detected 39 (2%) 27 (15%) 12 (7%)
EFV alone 10 5 5
NFV alone 9 9 -
IDV alone 5 1 4
SQV alone 5 5 -
EFV + IDV 3 - 3
TPV alone 2 2 -
NFV + SQV 2 2 -
EFV + NFV 1 1 -
ATV + IDV + NFV 1 1 -
EFV + IDV + NFV + SQV 1 1 -
The table shows the patterns of antiretroviral (ARV) drugs detected in plasma samples from HIV-uninfected participants enrolled in the HPTN 064 study.
Samples were screened for the presence of five nucleoside/nucleotide reverse transcriptase inhibitors, two non-nucleoside reverse transcriptase
inhibitors, and nine protease inhibitors. ARV drugs were detected in samples from participants enrolled at two of ten study communities, Baltimore, MD
and Bronx, NY. Abbreviations: ARV, antiretroviral; EFV, efavirenz; NFV, nelfinavir; IDV, indinavir; SQV, saquinavir; TPV, tipranavir; ATV, atazanavir.
doi:10.1371/journal.pone.0140074.t001
ARV Drug Use in HIV-UninfectedWomen
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Truvada1 (co-formulated FTC/TFV) was approved for PrEP in 2012 [1]. In contrast, EFV-
and PI-based regimens with dual NRTI backbones were recommended for PEP by the US
Department of Health and Human Services (DHHS) at that time [2,11]. The ARV drugs
detected in this study, with the exception of TPV, were consistent with drugs that were recom-
mended as part of PEP regimens during the study period. All of the HIV-uninfected women in
HPTN 064 who reported any prior ARV drug use also indicated that the drugs had been used
for PEP. We did not detect any NRTIs that are recommended components of triple-drug PEP
regimens. It is possible that some women were taking NRTIs that were not detected because of
the relatively short half-lives of these drugs. We also cannot exclude the possibility that plasma
storage impacted ARV drug detection. However, the samples tested in this study were stored at
-80°C prior to ARV drug testing, and several studies have documented the stability of ARV
drugs in frozen plasma samples [12–15].
Individuals who become HIV infected while using ARV drugs are at risk for acquiring ARV
drug resistance, and some ARV drugs are associated with toxic or unfavorable side effects and
negative drug-drug interactions [16]. It is notable that most of the PIs detected in this study
Table 2. Association of Antiretroviral Drug Detection and Demographic Characteristics of HIV-uninfected Study Participants in Baltimore, MD and
Bronx, NY.
Baltimore Bronx Baltimore and Bronx
ARV drugs detected ARV drugs detected ARV drugs detected
Baseline Yes No Yes No Yes No
Characteristic 27 154 P value 12 167 P value 39 321 P value
Median age (IQR) 31 (25, 37) 35 (26, 41) 0.41 34 (27, 38) 26 (22, 32) 0.011 33 (26, 37) 29 (23, 39) 0.10
Race Black 23 (85%) 143 (93%) 0.040 9 (75%) 106 (64%) 0.42 32 (82%) 249 (78%) 0.30
White 2 (7%) 9 (6%) 1 (8%) 42 (25%) 3 (8%) 51 (16%)
Mixed 0 (0%) 2 (1%) 0 (0%) 3 (2%) 0 (0%) 5 (2%)
Other 2 (7%) 0 (0%) 2 (17%) 16 (10%) 4 (10%) 16 (5%)
Hispanic ethnicity 1 (4%) 3 (2%) 0.48 6 (50%) 91 (55%) 0.76 7 (18%) 94 (29%) 0.14
Education < HS grad 13 (48%) 76 (49%) 0.99 7 (58%) 70 (42%) 0.48 20 (51%) 146 (46%) 0.67
HS grad 9 (33%) 51 (33%) 3 (25%) 47 (28%) 12 (31%) 98 (31%)
> HS grad 5 (19%) 27 (18%) 2 (17%) 50 (30%) 7 (18%) 77 (24%)
Marital status Single, sep, widowed, div 15 (56%) 98 (64%) 0.36 6 (55%) 88 (55%) 0.50 21 (55%) 186 (59%) 0.31
Married or cohabitating 9 (33%) 49 (32%) 3 (27%) 58 (37%) 12 (32%) 107 (34%)
Other 3 (11%) 7 (5%) 2 (18%) 13 (8%) 5 (13%) 20 (6%)
Unknown 0 0 1 8 1 8
Income $10,000 5 (19%) 12 (8%) 0.12 1 (8%) 24 (14%) 0.61 6 (15%) 36 (11%) 0.84
$10,001-$20,000 2 (7%) 12 (8%) 1 (8%) 18 (11%) 3 (8%) 30 (9%)
>$20,000 12 (44%) 54 (35%) 3 (25%) 64 (38%) 15 (39%) 118 (37%)
Unknown 8 (30%) 76 (49%) 7 (58%) 61 (37%) 15 (39%) 137 (43%)
Food Yes 14 (52%) 75 (49%) 0.76 9 (75%) 82 (49%) 0.08 23 (59%) 157 (49%) 0.24
insecurity No 13 (48%) 79 (51%) 3 (25%) 85 (51%) 16 (41%) 164 (51%)
The table shows the demographic characteristics of HIV-uninfected participants from Baltimore, MD and Bronx, NY whose plasma samples were
screened for antiretroviral (ARV) drugs. Fisher’s exact, chi-square and Wilcoxon rank sum tests were used to analyze the association between these
characteristics and ARV drug detection. P values <0.05 are bolded. Baseline characteristics are defined as follows: HS grad: high school graduation; sep:
separated; div: divorced; cohabitating: not married but living with partner; income: annual household income; food insecurity: concerned about having
sufficient food for self and family. Abbreviations: ARV: antiretroviral; IQR: interquartile range.
doi:10.1371/journal.pone.0140074.t002
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were not recommended for ART during the study period (e.g., due to toxicities and/or low effi-
cacy) [17]. Several women in this study also had unusual combinations of ARV drugs detected
(e.g., multiple PIs or EFV with one or more PIs). The US FDA and DHHS guidelines for PrEP,
PEP, or ART do not recommend using more than one PI, unless a PI is being boosted by RTV,
or using an NNRTI with a PI [1–3,11,16].
HIV-uninfected individuals may use ARV drugs for purposes other than HIV prevention.
The NRTIs, 3TC and TFV, are recommended for treating chronic hepatitis B virus infection
[4]; these NRTIs were not detected in this study. ARV drugs may also be used for recreational
reasons. Reports indicate that EFV is sometimes used for its psychoactive effects [5], while PIs,
most notably RTV, may be used to prolong the effects of certain recreational drugs [6]. In this
study, we did not find any associations between ARV drug detection and self-reported individ-
ual or partner substance use.
Limited data are available about the prevalence of ARV drug use among HIV-uninfected
individuals. Recent studies report that PrEP and PEP use has increased over time [18,19].
Table 3. Association of Antiretroviral Drug Detection with Behavioral Characteristics of HIV-uninfected Study Participants in Baltimore, MD and
Bronx, NY.
Baltimore Bronx Baltimore and Bronx
ARV drugs detected ARV drugs detected ARV drugs detected
Baseline Yes No Yes No Yes No
Characteristic 27 154 P value 12 167 P value 39 321 P value
Median number of partners (IQR) 2.0 (1.0, 6.0) 2.0 (1.0, 4.0) 0.74 2.5 (1.0, 3.0) 2.0 (1.0, 4.0) 0.99 2.0 (1.0, 3.0) 2.0 (1.0, 4.0) 0.63
Exchange sex for commoditiesa 13 (50%) 76 (51%) 0.92 3 (25%) 49 (29%) 1.00 16 (42%) 125 (40%) 0.76
Unknown HIV status of last partner 8 (30%) 66 (43%) 0.20 4 (33%) 56 (34%) 1.00 12 (31%) 122 (38%) 0.38
Condom use (vaginal) 4 (15%) 11 (7%) 0.25 4 (33%) 26 (16%) 0.12 8 (21%) 37 (12%) 0.12
Anal sex 12 (44%) 68 (44%) 0.98 5 (42%) 75 (45%) 0.83 17 (44%) 143 (45%) 0.91
Condom use (anal)b 0 (0%) 11 (16%) 0.20 0 (0%) 11 (15%) 1.00 0 (0%) 22 (15%) 0.13
Concurrencya 15 (56%) 72 (47%) 0.42 5 (42%) 68 (41%) 1.00 20 (51%) 140 (44%) 0.37
Self-reported STIa 4 (15%) 25 (16%) 1.00 1 (9%) 14 (8%) 1.00 5 (13%) 39 (12%) 0.80
Substance use 14 (52%) 86 (56%) 0.70 4 (33%) 69 (41%) 0.76 18 (46%) 155 (48%) 0.80
Binge drinkinga 9 (33%) 46 (30%) 0.73 3 (25%) 56 (34%) 0.75 12 (31%) 102 (32%) 0.89
Drug use 11 (41%) 56 (36%) 0.66 1 (8%) 24 (14%) 1.00 12 (31%) 80 (25%) 0.43
Depressive symptomsa 16 (59%) 68 (45%) 0.18 3 (30%) 55 (35%) 1.00 19 (51%) 123 (40%) 0.19
Any history of abuse 11 (41%) 53 (34%) 0.53 6 (50%) 54 (32%) 0.22 17 (44%) 107 (33%) 0.20
Any childhood abuse 18 (67%) 71 (46%) 0.049 7 (58%) 69 (41%) 0.25 25 (64%) 140 (44%) 0.015
The table shows characteristics of HIV-uninfected participants who were enrolled in Baltimore, MD and Bronx, NY (limited to participants whose samples
were screened for ARV drugs in this study). Study participants were asked to self-report characteristics within six months of enrollment, unless otherwise
specified. Fisher’s exact, chi-square, and Wilcoxon rank sum tests were used to analyze the association between these characteristics and ARV drug
detection. P values <0.05 are bolded. Baseline characteristics are defined as follows: Unknown HIV status of last partner: unknown HIV status of man with
whom had last vaginal sex; Condom use (vaginal): Condom used with last vaginal sex; Condom use (anal): Condom used with last anal sex;
Concurrency: self-report of sex with a man while involved in a sexual relationship with another man during the same period; Self-reported STI: Self-
reported sexually-transmitted infection, including gonorrhea, syphilis, or chlamydia infection; Substance use: At least weekly substance use (including
drug use or binge-drinking [4 drinks on 1 occasion]); Binge drinking: At least weekly binge-drinking (4 drinks on 1 occasion); Drug use: At least weekly
drug use (excluding cannabis); Depressive symptoms: score 7 using the Center for Epidemiologic Studies Depression (CES-D) scale. Abbreviations:
ARV: antiretroviral; IQR: interquartile range.
aSome participants did not respond to all of the questions asked. In these cases, the percentage was calculated among all of the respondents.
bThis percentage was calculated among participants who reported ever having anal sex.
doi:10.1371/journal.pone.0140074.t003
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However, these studies are limited to electronic prescription data, which may not reflect actual
PrEP and PEP use in the community. HIV-uninfected individuals may acquire ARV drugs
from health care providers or from other sources. ARV drug sharing for PrEP and PEP
between HIV-infected and HIV-uninfected men who have sex with men has been documented
in the US [20,21]. Some reports also indicate that ARV drugs may be traded, sold, or purchased
in illicit marketplaces [22,23]. Notably, one woman in HPTN 064 not only reported acquiring
ARV drugs for PEP, but also reported an intention to sell the drugs when asked about other
reasons for her ARV drug use.
In this study, we used a low cost, high-throughput assay to screen for multiple ARV drugs
in more than 2,000 samples. This assay makes it feasible to perform large-scale studies to gain
information about the prevalence and patterns of ARV drug use in different populations. This
assay also provides an objective, biomedical measure of ARV drug use. None of the women
who had ARV drugs detected in this study reported any prior ARV drug use. Nondisclosure of
ARV drug use has been reported in both clinical and research settings [24–27]. Women in
HPTN 064 who had ARV drugs detected may not have been known that these were ARV med-
ications or may not have been familiar with the term “antiretroviral”, which was used in the
study questionnaire. As PrEP and PEP use continues to expand, further research is needed to
explore the extent of ARV drug use among HIV-uninfected women, the means by which those
drugs are acquired, the reasons for their use, and their impact on HIV drug resistance.
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